Precigen Reports First Quarter 2023 Financial Results and Business Updates
– Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse™ immunotherapy in RRP demonstrated favorable safety profile and significant reduction in...
Source: prnewswire.com